PL4135840T3 - Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych - Google Patents

Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Info

Publication number
PL4135840T3
PL4135840T3 PL21732998.6T PL21732998T PL4135840T3 PL 4135840 T3 PL4135840 T3 PL 4135840T3 PL 21732998 T PL21732998 T PL 21732998T PL 4135840 T3 PL4135840 T3 PL 4135840T3
Authority
PL
Poland
Prior art keywords
soluble
treatment
amino acid
water
acid derivatives
Prior art date
Application number
PL21732998.6T
Other languages
English (en)
Inventor
Krzysztof KAMIŃSKI
Michał ABRAM
Marcin JAKUBIEC
Anna RAPACZ
Szczepan MOGILSKI
Gniewomir LATACZ
Marta STRUGA
Original Assignee
Uniwersytet Jagielloński
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński, Warszawski Uniwersytet Medyczny filed Critical Uniwersytet Jagielloński
Publication of PL4135840T3 publication Critical patent/PL4135840T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL21732998.6T 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych PL4135840T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
PCT/PL2021/050026 WO2021210997A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders

Publications (1)

Publication Number Publication Date
PL4135840T3 true PL4135840T3 (pl) 2025-05-12

Family

ID=76483335

Family Applications (2)

Application Number Title Priority Date Filing Date
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych

Country Status (7)

Country Link
US (1) US20230192608A1 (pl)
EP (2) EP4527384A3 (pl)
CN (1) CN115715219B (pl)
CA (1) CA3175613A1 (pl)
ES (1) ES3020435T3 (pl)
PL (2) PL243119B1 (pl)
WO (1) WO2021210997A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (pl) * 1992-03-05 1996-10-11 Pfizer
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Also Published As

Publication number Publication date
EP4135840B1 (en) 2025-01-08
EP4135840A1 (en) 2023-02-22
US20230192608A1 (en) 2023-06-22
ES3020435T3 (en) 2025-05-22
EP4527384A2 (en) 2025-03-26
PL243119B1 (pl) 2023-06-26
CN115715219A (zh) 2023-02-24
CN115715219B (zh) 2026-01-06
CA3175613A1 (en) 2021-10-21
WO2021210997A1 (en) 2021-10-21
PL433567A1 (pl) 2021-10-18
EP4527384A3 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
HUE073599T2 (hu) Módosított aminosav-származékok neurológiai betegségek és kiválasztott pszichiátriai rendellenességek kezelésére
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
MY146238A (en) Prodrugs of excitatory amino acids
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
EP4452331B8 (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
PL1663244T3 (pl) Pochodne pterydyny do leczenia chorób związanych z TNF-alfa
WO2009058729A3 (en) Thiazole carboxamide derivatives and their to treat cancer
EP4405355A4 (en) LSD DERIVATIVES, SYNTHESIS AND METHOD FOR TREATING DISEASES AND DISORDERS
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
WO2016051306A3 (en) Novel anthranilic acid derivatives
PL4135840T3 (pl) Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
WO2006021000A3 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon
CA3264922A1 (en) METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGPTL3
NZ759537A (en) Use of thiol compounds to treat neurological disease
PT3924349T (pt) Derivados de aminoácidos para o tratamento de doenças inflamatórias
IL147953A0 (en) Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation
WO2016112382A3 (en) Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors
WO2003006489A3 (en) Prodrugs of excitatory amino acids
HK40112016A (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40128585A (zh) Angptl3相关疾病和病症的治疗方法